Stifel Nicolaus Begins Coverage on Oruka Therapeutics (NASDAQ:ORKA)

Stifel Nicolaus began coverage on shares of Oruka Therapeutics (NASDAQ:ORKAFree Report) in a report released on Friday, MarketBeat.com reports. The brokerage issued a buy rating and a $49.00 target price on the stock.

ORKA has been the subject of a number of other research reports. Wedbush initiated coverage on Oruka Therapeutics in a research note on Wednesday, September 4th. They issued an outperform rating and a $40.00 price objective for the company. TD Cowen assumed coverage on Oruka Therapeutics in a research note on Monday, September 16th. They set a buy rating for the company. Lifesci Capital began coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They issued an outperform rating and a $41.00 price objective for the company. Jefferies Financial Group began coverage on Oruka Therapeutics in a report on Friday, September 13th. They issued a buy rating and a $40.00 target price on the stock. Finally, Leerink Partners initiated coverage on shares of Oruka Therapeutics in a research note on Tuesday, September 17th. They set an outperform rating and a $44.00 price objective for the company. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Oruka Therapeutics currently has an average rating of Buy and an average target price of $43.17.

Get Our Latest Research Report on Oruka Therapeutics

Oruka Therapeutics Stock Up 6.5 %

Oruka Therapeutics stock opened at $27.74 on Friday. Oruka Therapeutics has a 12-month low of $18.72 and a 12-month high of $53.88. The stock has a market cap of $33.57 million, a P/E ratio of -4.62 and a beta of 0.89.

Oruka Therapeutics (NASDAQ:ORKAGet Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($25.92) earnings per share for the quarter. As a group, equities research analysts predict that Oruka Therapeutics will post -1.62 earnings per share for the current year.

Oruka Therapeutics Company Profile

(Get Free Report)

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.

Further Reading

Analyst Recommendations for Oruka Therapeutics (NASDAQ:ORKA)

Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.